Status:
UNKNOWN
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant...
Eligibility Criteria
Inclusion
- Female patients, ≥18 Years.
- Epithelial ovarian, fallopian tube or primary peritoneal cancer
- Platinum refractory and resistant disease (disease progression during platinum therapy or within \<6 months of platinum therapy)
- EOCG performance status of 0-2
Exclusion
- Non-epithelial tumours
- Ovarian tumours with low malignant potential
- Surgery (including open biopsy) within 4 weeks before starting study therapy or anticipated need for major surgery during study treatment
- Evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04383977
Start Date
May 1 2020
End Date
June 1 2021
Last Update
May 12 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.